|Follow-up (closed to accrual)
|Study Start Date:
|Study Made Public:
A pivotal Phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in preventing HIV-1 infection in adults in South Africa
HVTN 702 is a Phase III clinical trial to evaluate the safety and immunogenicity of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59.
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.